Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Toward a Lifestyle Medicine Approach to Illness Anxiety Disorder (Formerly Hypochondriasis).

Chappell AS.

Am J Lifestyle Med. 2018 Apr 27;12(5):365-369. doi: 10.1177/1559827618764649. eCollection 2018 Sep-Oct. Review.

2.

Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.

Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, Hansson P, Haroutounian S, Arendt-Nielsen L, Attal N, Baron R, Brell J, Bujanover S, Burke LB, Carr D, Chappell AS, Cowan P, Etropolski M, Fillingim RB, Gewandter JS, Katz NP, Kopecky EA, Markman JD, Nomikos G, Porter L, Rappaport BA, Rice AS, Scavone JM, Scholz J, Simon LS, Smith SM, Tobias J, Tockarshewsky T, Veasley C, Versavel M, Wasan AD, Wen W, Yarnitsky D.

Pain. 2016 Sep;157(9):1851-71. doi: 10.1097/j.pain.0000000000000602. Review.

3.

Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.

Zwart R, Sher E, Ping X, Jin X, Sims JR Jr, Chappell AS, Gleason SD, Hahn PJ, Gardinier K, Gernert DL, Hobbs J, Smith JL, Valli SN, Witkin JM.

J Pharmacol Exp Ther. 2014 Oct;351(1):124-33. doi: 10.1124/jpet.114.212779. Epub 2014 Jul 15.

PMID:
25027316
4.

Results from clinical trials of a selective ionotropic glutamate receptor 5 (iGluR5) antagonist, LY5454694 tosylate, in 2 chronic pain conditions.

Chappell AS, Iyengar S, Lobo ED, Prucka WR.

Pain. 2014 Jun;155(6):1140-9. doi: 10.1016/j.pain.2014.02.023. Epub 2014 Mar 12.

PMID:
24631589
5.

Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy volunteers.

Petersen KL, Iyengar S, Chappell AS, Lobo ED, Reda H, Prucka WR, Verfaille SJ.

Pain. 2014 May;155(5):929-36. doi: 10.1016/j.pain.2014.01.019. Epub 2014 Jan 31.

PMID:
24486883
6.

Tailoring chronic pain treatments for the elderly: are we prepared for the challenge?

Arneric SP, Laird JM, Chappell AS, Kennedy JD.

Drug Discov Today. 2014 Jan;19(1):8-17. doi: 10.1016/j.drudis.2013.08.017. Epub 2013 Aug 31. Review.

PMID:
24001595
7.

Estimation of minimum clinically important difference for pain in fibromyalgia.

Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, Kajdasz DK, Walker DJ, Chappell AS.

Arthritis Care Res (Hoboken). 2011 Jun;63(6):821-6. doi: 10.1002/acr.20449.

8.

Effect of duloxetine in patients with fibromyalgia: tiredness subgroups.

Bradley LA, Bennett R, Russell IJ, Wohlreich MM, Chappell AS, Wang F, D'Souza DN, Moldofsky H.

Arthritis Res Ther. 2010;12(4):R141. doi: 10.1186/ar3081. Epub 2010 Jul 14.

9.

A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee.

Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, Brown JP.

Pain Pract. 2011 Jan-Feb;11(1):33-41. doi: 10.1111/j.1533-2500.2010.00401.x.

PMID:
20602715
10.

Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.

Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M.

Pain Med. 2010 May;11(5):648-57. doi: 10.1111/j.1526-4637.2010.00836.x. Epub 2010 Apr 13.

PMID:
20546509
11.

Efficacy and safety of duloxetine in patients with chronic low back pain.

Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M.

Spine (Phila Pa 1976). 2010 Jun 1;35(13):E578-85. doi: 10.1097/BRS.0b013e3181d3cef6.

PMID:
20461028
12.

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.

Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, Clawson L, Haas L, Rothstein JD.

Amyotroph Lateral Scler. 2010 May 3;11(3):266-71. doi: 10.3109/17482960903307805.

PMID:
19961264
13.

Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials.

Arnold LM, Clauw DJ, Wohlreich MM, Wang F, Ahl J, Gaynor PJ, Chappell AS.

Prim Care Companion J Clin Psychiatry. 2009;11(5):237-44. doi: 10.4088/PCC.08m00680.

14.

Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis.

Wohlreich MM, Sullivan MD, Mallinckrodt CH, Chappell AS, Oakes TM, Watkin JG, Raskin J.

Psychosomatics. 2009 Jul-Aug;50(4):402-12. doi: 10.1176/appi.psy.50.4.402.

PMID:
19687181
15.

Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain.

Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke MJ, Gross JL, Ziegler D.

Diabetes Metab Res Rev. 2009 Oct;25(7):623-31. doi: 10.1002/dmrr.1000.

PMID:
19637208
16.

Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial.

Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, Bennett RM, Collins H.

Pain. 2009 Dec;146(3):253-60. doi: 10.1016/j.pain.2009.06.024. Epub 2009 Jul 21.

PMID:
19625125
17.

Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.

Arnold LM, Hudson JI, Wang F, Wohlreich MM, Prakash A, Kajdasz DK, Chappell AS.

Clin J Pain. 2009 Jul-Aug;25(6):461-8. doi: 10.1097/AJP.0b013e318197d4e4.

PMID:
19542792
18.

Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.

Choy EH, Mease PJ, Kajdasz DK, Wohlreich MM, Crits-Christoph P, Walker DJ, Chappell AS.

Clin Rheumatol. 2009 Sep;28(9):1035-44. doi: 10.1007/s10067-009-1203-2. Epub 2009 Jun 18.

19.

A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia.

Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H.

Clin J Pain. 2009 Jun;25(5):365-75. doi: 10.1097/AJP.0b013e31819be587.

PMID:
19454869
20.

Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study.

Hunter AM, Leuchter AF, Cook IA, Abrams M, Siegman BE, Furst DE, Chappell AS.

Pain Med. 2009 May-Jun;10(4):730-8. doi: 10.1111/j.1526-4637.2009.00614.x. Epub 2009 Apr 22.

PMID:
19453962
21.

Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.

Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, Walker DJ, Chappell AS.

Semin Arthritis Rheum. 2010 Jun;39(6):454-64. doi: 10.1016/j.semarthrit.2008.11.001. Epub 2009 Jan 18.

PMID:
19152958
22.

A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.

Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M.

Int J Gen Med. 2008 Nov 30;1:91-102.

23.

The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder.

Fishbain DA, Detke MJ, Wernicke J, Chappell AS, Kajdasz DK.

Curr Med Res Opin. 2008 Nov;24(11):3105-15. doi: 10.1185/03007990802429627 . Epub 2008 Oct 2.

PMID:
18828958
24.

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.

Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM.

Pain. 2008 Jun;136(3):432-44. doi: 10.1016/j.pain.2008.02.024. Epub 2008 Apr 18.

PMID:
18395345
25.

Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review.

Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS.

Pain Med. 2007 Sep;8 Suppl 2:S50-62. Review.

PMID:
17714116
26.

An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.

Wernicke JF, Wang F, Pritchett YL, Smith TR, Raskin J, D'Souza DN, Iyengar S, Chappell AS.

Pain Med. 2007 Sep;8(6):503-13.

PMID:
17716324
27.

Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.

Armstrong DG, Chappell AS, Le TK, Kajdasz DK, Backonja M, D'Souza DN, Russell JM.

Pain Med. 2007 Jul-Aug;8(5):410-8. Erratum in: Pain Med. 2007 Nov-Dec;8(8):690.

PMID:
17661854
28.

AMPA potentiator treatment of cognitive deficits in Alzheimer disease.

Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R.

Neurology. 2007 Mar 27;68(13):1008-12.

PMID:
17389305
29.

Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.

Ziegler D, Pritchett YL, Wang F, Desaiah D, Robinson MJ, Hall JA, Chappell AS.

Diabetes Care. 2007 Mar;30(3):664-9.

PMID:
17327338
30.

Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects.

Jhee SS, Chappell AS, Zarotsky V, Moran SV, Rosenthal M, Kim E, Chalon S, Toublanc N, Brandt J, Coutant DE, Ereshefsky L.

J Clin Pharmacol. 2006 Apr;46(4):424-32.

PMID:
16554450
32.

LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.

Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F.

Cephalalgia. 2004 Jul;24(7):596-602.

PMID:
15196302
33.

A crossover, add-on trial of talampanel in patients with refractory partial seizures.

Chappell AS, Sander JW, Brodie MJ, Chadwick D, Lledo A, Zhang D, Bjerke J, Kiesler GM, Arroyo S.

Neurology. 2002 Jun 11;58(11):1680-2.

PMID:
12058100
34.
35.

Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats.

Belayev L, Alonso OF, Liu Y, Chappell AS, Zhao W, Ginsberg MD, Busto R.

J Neurotrauma. 2001 Oct;18(10):1031-8.

PMID:
11686490
36.

Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain.

Gilron I, Max MB, Lee G, Booher SL, Sang CN, Chappell AS, Dionne RA.

Clin Pharmacol Ther. 2000 Sep;68(3):320-7.

PMID:
11014414
37.

AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans.

Sang CN, Hostetter MP, Gracely RH, Chappell AS, Schoepp DD, Lee G, Whitcup S, Caruso R, Max MB.

Anesthesiology. 1998 Nov;89(5):1060-7.

PMID:
9821993
38.

Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.

Chappell AS, Bay JM, Botzum GD, Cohen ML.

Neuropharmacology. 1994 Mar-Apr;33(3-4):509-13.

PMID:
7984290
39.

Visual loss and performance in blind athletes.

Makris VI, Yee RD, Langefeld CD, Chappell AS, Slemenda CW.

Med Sci Sports Exerc. 1993 Feb;25(2):265-9.

PMID:
8450731

Supplemental Content

Loading ...
Support Center